132 related articles for article (PubMed ID: 9389917)
1. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
3. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
4. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome.
Semczuk A; Berbeć H; Kostuch M; Cybulski M; Wojcierowski J; Baranowski W
J Cancer Res Clin Oncol; 1998; 124(12):695-700. PubMed ID: 9879831
[TBL] [Abstract][Full Text] [Related]
5. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.
Sasaki H; Nishii H; Takahashi H; Tada A; Furusato M; Terashima Y; Siegal GP; Parker SL; Kohler MF; Berchuck A
Cancer Res; 1993 Apr; 53(8):1906-10. PubMed ID: 8467512
[TBL] [Abstract][Full Text] [Related]
6. Studies on ras oncogene activation in endometrial carcinoma.
Fujimoto I; Shimizu Y; Hirai Y; Chen JT; Teshima H; Hasumi K; Masubuchi K; Takahashi M
Gynecol Oncol; 1993 Feb; 48(2):196-202. PubMed ID: 8428691
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
9. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium.
Manavi M; Bauer M; Baghestanian M; Berger A; Kucera E; Pischinger K; Battistutti W; Czerwenka K
Tumour Biol; 2001; 22(5):299-309. PubMed ID: 11553860
[TBL] [Abstract][Full Text] [Related]
11. Detection of K-ras mutations in cancerous lesions of human endometrium.
Semczuk A; Berbéc H; Kostuch M; Kotarski J; Wojcierowski J
Eur J Gynaecol Oncol; 1997; 18(1):80-3. PubMed ID: 9061333
[TBL] [Abstract][Full Text] [Related]
12. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
13. Mutations and amplification of oncogenes in endometrial cancer.
Niederacher D; An HX; Cho YJ; Hantschmann P; Bender HG; Beckmann MW
Oncology; 1999; 56(1):59-65. PubMed ID: 9885379
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations.
Semczuk A; Skomra D; Cybulski M; Jakowicki JA
Histochem J; 2001 Apr; 33(4):193-200. PubMed ID: 11550800
[TBL] [Abstract][Full Text] [Related]
15. K-ras exon 2 point mutations in human endometrial cancer.
Semczuk A; Schneider-Stock R; Berbec H; Marzec B; Jakowicki JA; Roessner A
Cancer Lett; 2001 Mar; 164(2):207-12. PubMed ID: 11179836
[TBL] [Abstract][Full Text] [Related]
16. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Lab Invest; 1997 Jan; 76(1):109-16. PubMed ID: 9010454
[TBL] [Abstract][Full Text] [Related]
17. K-ras mutations in endometrial carcinomas with microsatellite instability.
Lagarda H; Catasus L; Arguelles R; Matias-Guiu X; Prat J
J Pathol; 2001 Feb; 193(2):193-9. PubMed ID: 11180166
[TBL] [Abstract][Full Text] [Related]
18. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the Ki-ras oncogene in endometrial carcinoma.
Ignar-Trowbridge D; Risinger JI; Dent GA; Kohler M; Berchuck A; McLachlan JA; Boyd J
Am J Obstet Gynecol; 1992 Jul; 167(1):227-32. PubMed ID: 1442931
[TBL] [Abstract][Full Text] [Related]
20. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.
Alexander-Sefre F; Salvesen HB; Ryan A; Singh N; Akslen LA; MacDonald N; Wilbanks G; Jacobs IJ
Gynecol Oncol; 2003 Oct; 91(1):218-25. PubMed ID: 14529685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
